Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Convalescent plasma (CP) from blood donors with anti-SARS-CoV-2 antibodies may benefit patients with COVID-19 by providing immediate passive immunity via transfusion, or when used to manufacture hyperimmune immunoglobulin preparations. Optimal product characteristics (including neutralizing antibody titers), volume of transfusion, and timing of administration remain to be determined. Preliminary safety data for COVID-19 CP are encouraging, but establishing the clinical efficacy of CP requires recruitment of patients to high-quality randomized trials and an ongoing international collaborative effort.

Original publication




Journal article



Publication Date